IP Verse

Subcutaneous Her2 Antibody Formulations - EP3570884

The patent EP3570884 was granted to F Hoffmann LA Roche on Sep 30, 2020. The application was originally filed on Jan 16, 2018 under application number EP18713735A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3570884

F HOFFMANN LA ROCHE
Application Number
EP18713735A
Filing Date
Jan 16, 2018
Status
Granted And Under Opposition
Aug 28, 2020
Grant Date
Sep 30, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEJun 30, 2021HOFFMANN EITLEADMISSIBLE
POHLMANJun 30, 2021POHLMANADMISSIBLE
WITHERS & ROGERSJun 28, 2021TOMBLINGADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEApr 22, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEApr 22, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (198) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2001014326
DESCRIPTIONUS2002001587
DESCRIPTIONUS2002035736
DESCRIPTIONUS2002064785
DESCRIPTIONUS2002090662
DESCRIPTIONUS2002136719
DESCRIPTIONUS2003134344
DESCRIPTIONUS2003147884
DESCRIPTIONUS2003152987
DESCRIPTIONUS2003170234
DESCRIPTIONUS2003202972
DESCRIPTIONUS2004008204
DESCRIPTIONUS2004037823
DESCRIPTIONUS2004048525
DESCRIPTIONUS2004106161
DESCRIPTIONUS2004258685
DESCRIPTIONUS2005002928
DESCRIPTIONUS2005063972
DESCRIPTIONUS2005100944
DESCRIPTIONUS2005208043
DESCRIPTIONUS2005238640
DESCRIPTIONUS2005244417
DESCRIPTIONUS2005244929
DESCRIPTIONUS2005276812
DESCRIPTIONUS2006013819
DESCRIPTIONUS2006018739
DESCRIPTIONUS2006018899
DESCRIPTIONUS2006034840
DESCRIPTIONUS2006034842
DESCRIPTIONUS2006046270
DESCRIPTIONUS2006067930
DESCRIPTIONUS2006073143
DESCRIPTIONUS2006083739
DESCRIPTIONUS2006088523
DESCRIPTIONUS2006099201
DESCRIPTIONUS2006121044
DESCRIPTIONUS2006165702
DESCRIPTIONUS2006183150
DESCRIPTIONUS2006188509
DESCRIPTIONUS2006193854
DESCRIPTIONUS2006198843
DESCRIPTIONUS2006204505
DESCRIPTIONUS2006210561
DESCRIPTIONUS2006212956
DESCRIPTIONUS2006275305
DESCRIPTIONUS2007009976
DESCRIPTIONUS2007020261
DESCRIPTIONUS2007026001
DESCRIPTIONUS2007037228
DESCRIPTIONUS2007166753
DESCRIPTIONUS2007184055
DESCRIPTIONUS2007224203
DESCRIPTIONUS2007269429
DESCRIPTIONUS2007292419
DESCRIPTIONUS2008038271
DESCRIPTIONUS2008050373
DESCRIPTIONUS2008050385
DESCRIPTIONUS2008050748
DESCRIPTIONUS2008102069
DESCRIPTIONUS2008108096
DESCRIPTIONUS2008112958
DESCRIPTIONUS2008160026
DESCRIPTIONUS2008171040
DESCRIPTIONUS2008187533
DESCRIPTIONUS2008226659
DESCRIPTIONUS2008241146
DESCRIPTIONUS2008317753
DESCRIPTIONUS2009081223
DESCRIPTIONUS2009087432
DESCRIPTIONUS2009098135
DESCRIPTIONUS2009148401
DESCRIPTIONUS2009148435
DESCRIPTIONUS2009155259
DESCRIPTIONUS2009187007
DESCRIPTIONUS2009202536
DESCRIPTIONUS2009202546
DESCRIPTIONUS2009220492
DESCRIPTIONUS2009226455
DESCRIPTIONUS2009239236
DESCRIPTIONUS2009285837
DESCRIPTIONUS2009317387
DESCRIPTIONUS2010008975
DESCRIPTIONUS2010015157
DESCRIPTIONUS2010016556
DESCRIPTIONUS2010112603
DESCRIPTIONUS2010120053
DESCRIPTIONUS2010158899
DESCRIPTIONUS2010285010
DESCRIPTIONUS2010298156
DESCRIPTIONUS2011027190
DESCRIPTIONUS2011033460
DESCRIPTIONUS2011044977
DESCRIPTIONUS2011064737
DESCRIPTIONUS2011117096
DESCRIPTIONUS2011117097
DESCRIPTIONUS2011129464
DESCRIPTIONUS2011165157
DESCRIPTIONUS2011236383
DESCRIPTIONUS4816567
DESCRIPTIONUS4933294
DESCRIPTIONUS4968603
DESCRIPTIONUS5183884
DESCRIPTIONUS5401638
DESCRIPTIONUS5480968
DESCRIPTIONUS5648237
DESCRIPTIONUS5677171
DESCRIPTIONUS5720937
DESCRIPTIONUS5720954
DESCRIPTIONUS5725856
DESCRIPTIONUS5770195
DESCRIPTIONUS5772997
DESCRIPTIONUS5821337
DESCRIPTIONUS6015567
DESCRIPTIONUS6054297
DESCRIPTIONUS6127526
DESCRIPTIONUS6165464
DESCRIPTIONUS6267958
DESCRIPTIONUS6333169
DESCRIPTIONUS6333398
DESCRIPTIONUS6339142
DESCRIPTIONUS6387371
DESCRIPTIONUS6399063
DESCRIPTIONUS6407213
DESCRIPTIONUS6417335
DESCRIPTIONUS6489447
DESCRIPTIONUS6573043
DESCRIPTIONUS6627196
DESCRIPTIONUS6632979
DESCRIPTIONUS6639055
DESCRIPTIONUS6685940
DESCRIPTIONUS6695940
DESCRIPTIONUS6719971
DESCRIPTIONUS6797814
DESCRIPTIONUS6800738
DESCRIPTIONUS6821151
DESCRIPTIONUS6821515
DESCRIPTIONUS6905830
DESCRIPTIONUS6949245
DESCRIPTIONUS6984494
DESCRIPTIONUS7018809
DESCRIPTIONUS7041292
DESCRIPTIONUS7060268
DESCRIPTIONUS7074404
DESCRIPTIONUS7097840
DESCRIPTIONUS7129840
DESCRIPTIONUS7279287
DESCRIPTIONUS7344840
DESCRIPTIONUS7371376
DESCRIPTIONUS7371379
DESCRIPTIONUS7435797
DESCRIPTIONUS7449184
DESCRIPTIONUS7468252
DESCRIPTIONUS7485302
DESCRIPTIONUS7485704
DESCRIPTIONUS7498030
DESCRIPTIONUS7501122
DESCRIPTIONUS7531645
DESCRIPTIONUS7537931
DESCRIPTIONUS7560111
DESCRIPTIONUS7575748
DESCRIPTIONUS7618631
DESCRIPTIONUS7674589
DESCRIPTIONUS7682609
DESCRIPTIONUS7700299
DESCRIPTIONUS7807799
DESCRIPTIONUS7811773
DESCRIPTIONUS7846441
DESCRIPTIONUS7850966
DESCRIPTIONUS7862817
DESCRIPTIONUS7879325
DESCRIPTIONUS7892549
DESCRIPTIONUS7981418
DESCRIPTIONUS7993834
DESCRIPTIONUS8372396
DESCRIPTIONUS8404234
DESCRIPTIONUS9017671
DESCRIPTIONUS9345661
DESCRIPTIONWO0189566
DESCRIPTIONWO2004078140
DESCRIPTIONWO2006044908
DESCRIPTIONWO2006091871
DESCRIPTIONWO9105264
DESCRIPTIONWO9704801
DESCRIPTIONWO9845479
DESCRIPTIONWO9931140
INTERNATIONAL-SEARCH-REPORTUS2011044977
OPPOSITIONUS2005208043
OPPOSITIONUS2006088523
OPPOSITIONUS2011044977
OPPOSITIONUS2011117097
OPPOSITIONUS2018013854
OPPOSITIONWO2006044908
OPPOSITIONWO2006078307
OPPOSITIONWO2008031531
OPPOSITIONWO2011012637
OPPOSITIONWO2016044334
OPPOSITIONWO2016044396
OPPOSITIONWO9704801

Non-Patent Literature (NPL) Citations (82) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Alfred Goodman Gilman; Grant R. Wilkinson, "SECTION I: GENERAL PRINCIPLES: Introduction; Chapter 1. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination", Alfred Goodman Gilman; Grant R. Wilkinson, Joel G. Hardman (ed.), Goodman and Gilman’s The Pharmacological Basis of Therapeutics, McGraw Hill , (20010101), pages 3 - 29, ISBN 0-07-112432-2, XP009527304
OPPOSITION- Anonymous, "A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC)", ClinicalTrials.org NCT02738970, (20160701), pages 1 - 10, XP055823290
OPPOSITION- Anonymous, "APPLICATION NUMBER: 125409Orig1s000 PHARMACOLOGY REVIEW(S)", CENTER FOR DRUG EVALUATION AND RESEARCH, (20120516), CENTER FOR DRUG EVALUATION AND RESEARCH, (20220705), XP055938449
OPPOSITION- Anonymous, "Assessment report Perjeta International non-proprietary name: PERTUZUMAB", EMA, (20121213), EMA, (20220705), XP055938369
OPPOSITION- Anonymous, "Genentech's Omnitarg fails in Phase", PharmaTimes, (20050000), pages 1 - 2, XP055824387
OPPOSITION- Anonymous, "Herceptin - CHMP assessment report", European Medicines Agency, (20130627), pages 1 - 70, XP055824328
OPPOSITION- Anonymous, "Herceptin ", EMA, (20210101), XP055938381
OPPOSITION- Anonymous, "HERCEPTIN Reference ID: 3903664", HERCEPTIN, (20160300), pages 1 - 37, XP055824099
OPPOSITION- Anonymous, "History of Changes for Study: NCT02019277 A Study of Pertuzumab and Trastuzumab 1rreatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic B,reast Cancer", Clinicaltrials.gov on NCT02019277, (20161101), Clinicaltrials.gov on NCT02019277, URL: https://clinicaltrials.gov/ct2/history/NCT02019277?V_ 56=View#StudyPageTop, (20220705), XP055938413
OPPOSITION- Anonymous, "History of Changes for Study: NCT02738970 A Dose-Finding Study of Pertuzumab (PE!rjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC)", Clinicaltrials.gov on NCT02738970, (20160701), Clinicaltrials.gov on NCT02738970, URL: https://clinicaltrials.gov/ct2/history/NCT02738970?V_ 4=View#StudyPage Top, (20220705), XP055938426
OPPOSITION- Anonymous, "HYLENEX - highlights of prescribing information", HYLENEX, (20160200), pages 1 - 9, XP055824382
OPPOSITION- Anonymous, "Immunoglobulin G wikipedia", Wikipedia, (20161028), pages 1 - 5, XP093181644
OPPOSITION- Anonymous, "Look around as a guest", San Antonio Breast Cancer Symposium, (20171205), URL: https://sabcs17.posterview. com/nosl/?searchterm=p5-20-07 &searchtvpe=Keyword
OPPOSITION- Anonymous, " Pertuzumab SPECIAL PRECAUTIONS", BC Cancer Agency Cancer Drug Manual, (20140101), BC Cancer Agency Cancer Drug Manual, (20220705), XP055938443
OPPOSITION- Anonymous, "RPERJETA™ pertuzumab 420 mg/14 mL vial Concentrate for solution for infusion Antineoplastic Professed StandaRD", PRODUCT MONOGRAPH, (20130412), PRODUCT MONOGRAPH , (20220705), XP055938432
OPPOSITION- Anonymous, "trastuzumab, 600 mg/5ml solution for injection (Herceptin®", NHS SCOTLAND, (20140113), XP055938387
OPPOSITION- BABU MEDI et al., "Excipient selection in biologics and vaccines formulation development", European Pharmaceutical Review, (20140219), pages 1 - 13, XP055940601
OPPOSITION- Basel, "Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion", Roche Media Release, (20120323), pages 1 - 5, XP055823330
OPPOSITION- B. Bittner, W. F. Richter, F. Hourcade-Potelleret, C. McIntyre, F. Herting, M. L. Zepeda, J. Schmidt, "Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen", Arzneimittelforschung, vol. 62, (20120000), pages 401 - 409, URL: http://dx.doi.org/10.1055/s-0032-1321831, XP055824302
OPPOSITION- BERGER et al., "Bioavailability of IgG Administered y the Subcutaneous Route", J. Clin. Immunol., (20130000), vol. 33, pages 984 - 990, XP055824091
OPPOSITION- Bittner B; Richter W F; Hourcade-Potelleret F; Mcintyre C; Herting F; Zepeda M L; Schmidt J, "Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen", Arzneimittelforschung, (20120000), vol. 62, pages 401 - 409, XP055824302
OPPOSITION- Bittner B., W. F. Richter, F. Hourcade-Potelleret, C. Mcintyre, F. Herting, M. L. Zepeda, J. Schmidt, "Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen", ARZNEIMITTELFORSCHUNG, (20120101), vol. 62, pages 401 - 409, XP055824302
OPPOSITION- Brent S. Kendrick et al., "Peferentially excluded cosolvents", Brent S. Kendrick et al., CARPENTER et al., Rationale Design of Stable Protein Formulations-Theory and Practice, (20020000), pages 186 - 188, XP055824129
OPPOSITION- Christoph Zielinski,, Wien, Drach Johannes, "Pertuzumab", Medizin Medien Austria, Martin Widschwendter, (20160301), XP055938373
OPPOSITION- Clinicaltrials.gov on NCT02402712, (20161101), URL: https://clinicaltrials.gov/ct2/history/NCT02402712?V_ 23= View#StudyPage T op, XP055938411
OPPOSITION- FDA, Approval package, (20141028), URL: https://web.archive.org/web/ 20141028 115225/ http:/www.accessdata.fda.gov/drugsatfda_ docs/nda/2012/125409Orig 1 s000TOC.cfm
OPPOSITION- GENENTECH INC. et al., "A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA", ClinicalTrials.gov, (20071204), pages 1 - 37, XP055824359
OPPOSITION- HAZIMI et al., "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", Onco Targets Ther, (20130000), vol. 6, pages 89 - 94, XP055938385
OPPOSITION- HOFFMAN-LA ROCHE, "History of Changes for Study: NCT02019277 A Study of Pertuzumab and Trastuzumab Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", U.S. National Library of Medicine ClinicalTrials.gov, (20161101), pages 1 - 13, URL: https://clinicaltrials.gov/ct2/show/NCT02019277, XP055940625
OPPOSITION- HOFFMAN-LA ROCHE, "History of Changes for Study: NCT02738970 A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC)", U.S. National Library of Medicine ClinicalTrials.gov, (20160701), page 12, URL: https://www.clinicaltrials.gov/ct2/show/NCT02738970, XP055940621
OPPOSITION- HOFFMANN-LA ROCHE, "A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC", clinicaltrials.gov, (20210524), pages 1 - 12, URL: https://clinicaltrials.gov/ct2/show/NCT02738970, XP055823589
OPPOSITION- HOFFMANN-LA ROCHE, "A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (SAPPHIRE", ClinicalTrials.gov, (20131224), pages 1 - 12, XP055824379
OPPOSITION- HOFFMANN-LA ROCHE, "A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY", ClinicalTrials.gov, (20110524), pages 1 - 48, XP055824356
OPPOSITION- HOFFMANN-LA ROCHE, "A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer", .CLINICALTRIALS.GOV, (20071017), pages 1 - 85, XP055824370
OPPOSITION- HOFFMANN-LA ROCHE, "A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer", ClinicalTrials.gov, (20090731), pages 1 - 75, XP055824348
OPPOSITION- ISMAEL et al., "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomized trial", Lancet Onco l, (20120000), vol. 13, pages 869 - 878, XP055878003
OPPOSITION- Javier Cortés 1, Pierre Fumoleau, Giulia Valeria Bianchi, Teresa M Petrella, Karen Gelmon, Xavier Pivot, Shailendra Verma, Joan Albanell, Pierfranco Conte, Ana Lluch, Stefania Salvagni, Veronique Servent, Luca Gianni, Maurizio Scaltriti, Graham A Ross, Joanna Dixon, Tania Szado, José Baselga, "Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer", J. Clin. Oncol., (20120000), vol. 30, pages 1594 - 1600, XP055824120
OPPOSITION- Kambham Venkateswarlu, "Review on bioavailability and bioequivalence studies", International journal of pharmaceutical sciences review and research, Global Research Online Publishing House, IN, IN , (20130201), vol. 18, no. 1, ISSN 0976-044X, pages 56 - 64, XP093157502
OPPOSITION- KIRSCHBROWN et al., Proceedings of the 2017 San Antonio Breast Cancer Symposium, (20150000), page 3
OPPOSITION- Kirschbrown W. P., Et Al., "A phase lb dose-finding study of subcutaneous pertuzumab in combination with trastuzumab in healthy male volunteers and female patients with early breast cancer", San Antonio Breast Cancer Symposium, (20170000), page 1, XP055824340
OPPOSITION- Kirschbrown W. P., Et Al., "A phase lb dose-finding study of subcutaneous pertuzumab in combination with trastuzumab in healthy male volunteers and female patients with early breast cancer", San Antonio Breast Cancer Symposium, (20170101), page 1, San Antonio Breast Cancer Symposium, (20210714), XP055824340
OPPOSITION- KÜMMEL et al., "Abstract OT3-01-13: MetaPHER: A phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer", 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, (20151212), XP055938400
OPPOSITION- Lagner, Borchert, "4.3 PHARMAKOKINETISCHE MODELLE ", Biopharmazie, (20110101), pages 117 - 149, XP055938461
OPPOSITION- METZGER-FILHO et al., "Pertuzumab: optimizing HER2 blockade", Clin. Cancer Res., (20130000), vol. 19, no. 20, pages 5552 - 5556, XP055823436
OPPOSITION- MICHAEL E. AULTON, "Assessment of pharmaceutical properties", Aulton's Pharmaceutics-The Design and Manufacture of Medicines, (20070000), pages 317 - 319, XP055824151
OPPOSITION- MOYA-HORNO et al., "The expanding role of pertuzumab in the treatment of HER2-positive breast cancer", Breast Cancer: Targets and Therapy, (20150000), vol. 7, XP055824205
OPPOSITION- Moya-Horno, Et Al., "The expanding role of pertuzumab in the treatment of HER2-positive breast cancer", BREAST CANCER: TARGETS AND THERAPY, (20150101), vol. 7, pages 125 - 132, XP055824205
OPPOSITION- PELIKAN, EW., "Glossary of Terms and Symbols Used in Pharmacology", Pharmacology and Experimental Therapeutics, (19950000), pages 1 - 35, URL: https://www.bumc.bu.edu/busm-pm/academics/resources/ glossa ry/ # l, XP055940636
OPPOSITION- Pfeiffer, "6.2 FAKTOREN", Biopharmazie, (19950101), pages 144 - 191, XP055938468
OPPOSITION- Pivot X, J Gligorov , V Müller , G Curigliano , A Knoop , S Verma 6, V Jenkins , N Scotto , S Osborne , L Fallowfield, Prefher Study Group, "Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study", Annals of Oncology, (20140101), vol. 25, pages 1979 - 1987, XP055824228
OPPOSITION- ROWE et al., "Handbook of Pharmaceutical Excipients", Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090000), pages 1 - 917
OPPOSITION- Summary of Product Characteristics (SmPC) of Herceptin
OPPOSITION- Summary of Product Characteristics (SmPC) of Perjeta
OPPOSITION- WOODWARD et al., "Abstract P 4-14 -12: Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE", 3 8th Annual CTRC-AACR San Antonio Breast Cancer Symposium, XP055938409
OPPOSITION- WYNNE et al., "Comparison of Subcutaneous and Intravenous Administration of Trastuzumab : A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer", The Journal of Clinical Pharmacology, (20130000), vol. 53, no. 2, pages 192 - 201, XP055823259
OPPOSITION- WYNNE et al., "Comparison of subcutaneous and intravenous administration of trastuzumab: a phase l/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer", J. Clin. Pharmacol., (20130000), vol. 53, no. 2, pages 192 - 201, XP055823259
OPPOSITION- Wynne, Et Al., "Comparison of subcutaneous and intravenous administration of trastuzumab: a phase l/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer", J. Clin. Pharmacol., (20130101), vol. 53, no. 2, pages 192 - 201, XP055823259
OPPOSITION- X Pivot , J Gligorov , V Müller , G Curigliano , A Knoop , S Verma 6, V Jenkins , N Scotto , S Osborne , L Fallowfield, PrefHer Study Group, "Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study", Annals of Oncology, (20140000), vol. 25, pages 1979 - 1987, XP055824228
OPPOSITION- Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal, Russ Wada, Hanbin Li, Bei Wang, Ihsan Nijem, Tanja Badovinac Crnjevic, Helena Gasser, Sarah Heeson, Jennifer Eng‐wong, Amit Garg, "Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20190501), vol. 59, no. 5, doi:10.1002/jcph.1362, ISSN 0091-2700, pages 702 - 716, XP055770323
OPPOSITION- GLOVER et al., "Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration", J Pharm Sci., (20130000), vol. 102, no. 3, doi:10.1002/jps.23403, pages 794 - 812, XP055056389
OPPOSITION- GARG et al., "Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors", Cancer Chemother Pharmacol, (20140000), vol. 74, doi:10.1007/s00280-014-2560-3, pages 819 - 829, XP035397539
OPPOSITION- QUARTIN O et al., "Population pharmacokitenic and exposure-respnse analysis for trastuzumab administered using a subcutaneous ''manual syringe'' injection or intravenously in women with HER''-positive early breast cancer", Cancer Chemother Pharmacol, (20160000), vol. 77, pages 77 - 88, XP035593965
OPPOSITION- WASSERMAN, "Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again", J Clin Immunol., (20120000), vol. 32, no. 6, doi:10.1007/s10875-012-9740-x, pages 1153 - 1164, XP035153753
OPPOSITION- MCCORMACK, "Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer", Drugs, (20130000), vol. 73, no. 13, doi:10.1007/s40265-013-0109-0, pages 1491 - 1502, XP055637585
OPPOSITION- Stoner Kelly L, Harder Helena, Fallowfield Lesley J, Jenkins Valerie A, "Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review", Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews, (20140000), page 1, XP055940647
OPPOSITION- SHPILBERG et al., "Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase", BJC, (20130000), vol. 109, doi:10.1038/bjc.2013.371, pages 1556 - 1561, XP002782443
OPPOSITION- Bittner B., Richter W., Hourcade-Potelleret F., Herting F., Schmidt J., "Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab", Drug Research, Georg Thieme Verlag, DE, DE , (20140101), vol. 64, no. 11, doi:10.1055/s-0033-1363993, ISSN 2194-9379, pages 569 - 575, XP055857994
OPPOSITION- JACKISCH et al., "Subcutaneous Administration of Monoclonal Antibodies in Oncology", Geburtshilfe Frauenheilkd, (20140000), vol. 74, no. 4, doi:10.1055/s-0034-1368173, pages 343 - 349, XP055344155
OPPOSITION- BASELGA et al., "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer", N Eng J Med, (20120112), vol. 366, no. 2, doi:10.1056/NEJMoa1113216, pages 109 - 119, XP055057318
OPPOSITION- José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain, "Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer", New England Journal of Medicine, (20120000), vol. 366, no. 2, pages 109 - 19, XP055057318
OPPOSITION- ARTHUR, "Innovations in subcutaneous infusions", Infusion Nurses Society, (20150000), vol. 38, no. 3, doi:10.1097/NAN.0000000000000099, pages 179 - 187, XP009510495
OPPOSITION- SCHEUER et al., "Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination", Cancer Res, (20090000), vol. 69, no. 24, doi:10.1158/0008-5472.CAN-08-4597, pages 9330 - 9337, XP055029437
OPPOSITION- FRIESS et al., "Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts is Superior to Monotherapy", Clin Cancer Res, (20050000), vol. 11, no. 14, doi:10.1158/1078-0432.CCR-04-2642, pages 5300 - 5309, XP002537485
OPPOSITION- Wynne Chris, Harvey Vernon, Schwabe Christian, Waaka Devonie, Mcintyre Christine, Bittner Beate, "Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2- positive breast cancer", The Journal of Clinical Pharmacology, (20130200), vol. 53, no. 2, pages 192 - 201, XP055940617
OPPOSITION- FUENTES et al., "Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism", Breast Cancer Res., (20110000), vol. 13, no. 3, doi:10.1186/bcr2888, page R54, XP021104479
OPPOSITION- AGUS et al., "Phase / Clinical study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer", Journal of Clinical Oncology, (20050000), vol. 23, no. 11, doi:10.1200/JCO.2005.03.184, pages 2534 - 2543, XP008058275
OPPOSITION- Richter Wolfgang F.; Bhansali Suraj G.; Morris Marilyn E., "Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration", The AAPS Journal, Springer US, Boston, Boston , (20120523), vol. 14, no. 3, doi:10.1208/s12248-012-9367-0, pages 559 - 570, XP035719285
OPPOSITION- Frost Gregory I, "Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration", Expert Opin. Drug Deliv., (20070000), vol. 4, no. 4, pages 427 - 440, XP008177677
OPPOSITION- Frost Gregory I, "Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.", Expert Opinion on Drug Delivery, Informa Healthcare, GB, GB , (20070701), vol. 4, no. 4, doi:10.1517/17425247.4.4.427, ISSN 1742-5247, pages 427 - 440, XP008177677
OPPOSITION- FROST, "Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration", Expert Opin. Drug Deliv., (20070000), vol. 4, no. 4, doi:10.1517/17425247.4.4.427, pages 427 - 440, XP008177677
OPPOSITION- Salima Hamizi Freyer Gilles; Bakrin Naoual; Henin Emilie; Mohtaram Amina; Le Saux Olivia; Falandry Claire, "Subcutaneous trastuzumab: development f a new formulation for treatment of HER2-positive early breast cancer", Onco Targets and Therapy, (20130000), vol. 2013, no. 6, pages 89 - 94, XP055476980
OPPOSITION- ZHENG et al., "Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration", mAbs, (20120000), vol. 4, no. 2, doi:10.4161/mabs.4.2.19387, pages 243 - 255, XP055312728

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents